THE INTRODUCTION OF ETANERCEPT BIOSIMILAR IN THE PRACTICE OF A TERTIARY RHEUMATOLOGIC CENTRE IN ITALY: A BUDGET IMPACT MODEL

被引：1
|
作者：
Becciolini, A. [1 ]
Psachoulia, E. [2 ]
Biggioggero, M. [3 ,4 ]
Crotti, C. [3 ,4 ]
Agape, E. [3 ,4 ]
Negrini, C. [5 ]
Favalli, E. G. [1 ]
机构：
[1] Gaetano Pini Inst, Milan, Italy
[2] Biogen Int GmbH, Zug, Switzerland
[3] Univ Milan, Milan, Italy
[4] Gaetano Pini Inst, Milan, Italy
[5] Biogen Italia Srl, Milan, Italy
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.1092
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMS25
引用
收藏
页码：A534 / A534
页数：1
相关论文
共 50 条
  • [1] Budget impact analysis of the etanercept biosimilar: the Italian scenario
    Ravasio, Roberto
    Girolomoni, Giampiero
    Gorla, Roberto
    [J]. GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2018,
  • [2] IMPACT OF BLOCK SWITCH TO BIOSIMILAR ETANERCEPT IN PRACTICE - AN EXPERIENCE FROM ONE TERTIARY RHEUMATOLOGY DEPARTMENT
    Brites, Luisa
    Costa, Flavio
    de Freitas, Joao Dinis
    Luis, Mariana
    Coutinho, Margarida
    Santiago, Mariana
    Salvador, Maria Joao
    Duarte, Catia
    Jose Antonio Da Silva, P.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1372 - 1372
  • [3] BUDGET IMPACT ANALYSIS OF AN ETANERCEPT BIOSIMILAR FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN EUROPE
    Ruff, L.
    Rezk, M. F.
    Uhlig, T.
    Gommers, J. W.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A639 - A639
  • [4] BUDGET IMPACT ANALYSIS OF AN ETANERCEPT BIOSIMILAR FOR THE TREATMENT OF ALL LICENSED ETANERCEPT INDICATIONS FOR ADULTS IN EUROPE
    Ruff, L.
    Rezk, M. F.
    Uhlig, T.
    Gommers, J. W.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A639 - A639
  • [5] The Economic Impact of the Introduction of Infliximab-Biosimilar: Preliminary Results from a Study on Rheumatologic Patients in Tuscany, Italy
    Lorenzoni, Valentina
    Trieste, Leopoldo
    Mosca, Marta
    Convertino, Irma
    Tuccori, Marco
    Lucenteforte, Ersilia
    Ferraro, Sara
    Leonardi, Luca
    Roberto, Giuseppe
    Luciano, Nicoletta
    Blandizzi, Corrado
    Gini, Rosa
    Turchetti, Giuseppe
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 9 - 9
  • [6] IMPACT OF ETANERCEPT BIOSIMILAR LAUNCHES ON HEALTHCARE SPENDING: A UK BUDGET IMPACT MODEL FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND CHRONIC PLAQUE PSORIASIS
    Bhattacharyya, S.
    Banerjee, S.
    Clinton, H.
    Faithfull, G.
    Mendoza, C.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A580 - A581
  • [7] ESTIMATION OF THE BUDGET SAVING POTENTIAL DUE TO THE INTRODUCTION OF BENEPALI®, AN ETANERCEPT BIOSIMILAR, FOR THE TREATMENT OF ALL LICENSED ADULT ETANERCEPT INDICATIONS IN SPAIN
    Psachoulia, E.
    Casahorran, V
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A533 - A534
  • [8] Impact of Block Switch to Biosimilar Etanercept in Practice, Across Different Rheumatic Diseases
    Brites, Luisa
    Costa, Flavio
    Freitas, Joao
    Luis, Mariana
    Coutinho, Margarida
    Santiago, Mariana
    Duarte, Catia
    Salvador, Maria Joao
    da Silva, Jose Antonio P.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [9] ESTIMATION OF THE BUDGET SAVING POTENTIAL DUE TO THE INTRODUCTION OF AN ETANERCEPT BIOSIMILAR (SB4) FOR THE TREATMENT OF APPROVED ADULT ETANERCEPT INDICATIONS IN BELGIUM
    Psachoulia, E.
    Bresson, A.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A529 - A529
  • [10] Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives
    Rognoni, Carla
    Bertolani, Arianna
    Jommi, Claudio
    [J]. GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2018,
12345